Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S. ...Middle East

SUZHOU, China, April 25, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male...

Hence then, the article about kintor pharmaceuticals announces successful proxalutamide covid 19 phase iii clinical trial initiation and patient dosing in u s was published today ( Sunday 25/04/2021 - 05:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S. )

Also on site :

• Dunkin’s Limited-Edition Tumbler Is Already in High Demand—How to Get Yours
• World Cup 2026: Day five
• Did 'Summer House: The Aftermath' Just Hard Launch Amanda Batula's Redemption Arc? Some Fans Say 'Too Late'